ACPE Numbers: Various – see listing below
Release Date: 10/10/2018
Expiration Dates: 04/09/2019
Activity Type: Application-based
CE Credits: 10 hours
Activity Fee: $50 (ASHP member); $100 (non-member); $35 (Resident Member)
Accreditation for Pharmacists
ASHP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:
- General Pediatrics
- New guidelines for screening and management of high blood pressure in children and adolescents
- Safety of cough and cold medication use in pediatrics
- Neonatal and General Pediatrics
- Tezacaftor-ivacaftor for cystic fibrosis
- Buprenorphine for neonatal abstinence syndrome
- Effectiveness of prenatal versus postpartum vaccination in preventing infant pertussis
The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice and includes a short video for enhanced learning and understanding.
Module 2A - General Pediatrics: This module focuses on new guidelines for screening and management of high blood pressure in children and adolescents and the safety of cough and cold medication use in pediatrics.
Module 2B – Neonatal and General Pediatrics: This module focuses on tezacaftor-ivacaftor for cystic fibrosis, buprenorphine for neonatal abstinence syndrome, and effectiveness of prenatal versus postpartum vaccination in preventing infant pertussis.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.
Board certified pharmacists are eligible to receive up to 10 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.
*Assessment Pass Point
Pediatric Pharmacy Recertification Literature Study Module 2A: General Pediatrics
Pediatric Pharmacy Recertification Literature Study Module 2B: Neonatal and General Pediatrics
Articles and Learning Objectives
Module 2A - General Pediatrics
This module focuses on new guidelines for screening and management of high blood pressure in children and adolescents and the safety of cough and cold medication use in pediatrics.
Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3):e20171904.
- Describe the epidemiology, clinical importance, etiology, screening, and diagnosis of elevated blood pressure and hypertension in children and adolescents.
- Discuss the recommendations for nonpharmacologic and pharmacologic treatment of hypertension in the American Academy of Pediatrics clinical practice guideline.
- Explain considerations in managing hypertension in children and adolescents with comorbidities, including chronic kidney disease and diabetes mellitus.
- Recommend antihypertensive drug therapy for a child or adolescent with hypertension, taking into consideration patient characteristics and the American Academy of Pediatrics clinical practice guideline.
Green JL, Wang GS, Reynolds KM et al. Safety Profile of Cough and Cold Medication Use in Pediatrics. Pediatrics. 2017;139(6):e20163070.
- Describe the rationale, methodology, and limitations of the study of adverse events associated with cough and cold medication use in pediatric patients less than 12 years of age.
- Compare and contrast the typical patient age and sex, person administering the drug, location of exposure (home vs. other location), and product type associated with reports of adverse events from cough and cold medications in pediatric patients less than 12 years of age.
- Make a recommendation to improve the safety of cough and cold medications in pediatric patients less than 12 years of age.
Module 2B - Neonatal and General Pediatrics
This module focuses on tezacaftor-ivacaftor for cystic fibrosis, buprenorphine for neonatal abstinence syndrome, and effectiveness of prenatal versus postpartum vaccination in preventing infant pertussis.
Kraft WK, Adeniyi-Jones SC, Ehrlich ME et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med. 2017; 377(10):997-8. doi: 10.1056/NEJMc1709121.
- Describe the rationale, methodology, and limitations of the BBORN study of buprenorphine for the treatment of neonatal abstinence syndrome.
- Compare and contrast the efficacy and safety of oral morphine and sublingual buprenorphine for the treatment of neonatal abstinence syndrome.
- Make a recommendation for the treatment of neonatal abstinence syndrome.
Winter K, Nickell S, Powell M et al. Effectiveness of Prenatal Versus Postpartum Tetanus, Diphtheria, and Acellular Pertussis Vaccination in Preventing Infant Pertussis. Clin Infect Dis. 2017; 64(1):3-8.
- Describe the rationale, methodology, and limitations of the study of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis (Tdap) vaccination for preventing infant pertussis.
- Compare and contrast the effectiveness of tetanus, diphtheria, and acellular pertussis (Tdap) vaccination at various times during pregnancy and postpartum for preventing pertussis in infants less than 8 weeks of age and up to 12 weeks of age.
- Make recommendations for tetanus, diphtheria, and acellular pertussis (Tdap) vaccination in pregnant women.
Taylor-Cousar JL, Munck A, McKone EF et al. Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017; 377:2013-23.
- Describe the rationale, methodology, and limitations of the EVOLVE study of tezacaftor-ivacaftor in pediatric patients with cystic fibrosis.
- Describe the efficacy and safety of tezacaftor-ivacaftor in pediatric patients based on the findings from the EVOLVE study.
- Make a recommendation for the use of tezacaftor-ivacaftor in a pediatric patient with cystic fibrosis.
- Assess the safety and efficacy of tezacaftor-ivacaftor in a pediatric patient with cystic fibrosis.
Jennifer Dannelley, Pharm.D.
OU College of Medicine, Department of Pediatrics
Oklahoma City, Oklahoma
Kelly L. Matson, Pharm.D., BCPPS
University of Rhode Island
Kingston, Rhode Island
Pediatric Clinical Specialist
UMass Memorial Children's Medical Center
Jill Morgan, Pharm.D., BCPS, BCPPS
Associate Professor and Chair
University of Maryland School of Pharmacy
Pooja Shah, Pharm.D., BCPPS
Clinical Assistant Professor
Ernest Mario School of Pharmacy
Piscataway Township, New Jersey
Content Matter Experts
Peter N. Johnson, Pharm.D., BCPPS, BCPS, FPPAG
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Clinical Specialist, Pediatric Critical Care
The Children's Hospital at OU Medical Center
Oklahoma City, Oklahoma
Jamie L. Miller, Pharm.D., BCPPS, BCPS
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma
Jennifer L. Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York
Michelle C. Abalos, Pharm.D.
Susan R. Dombrowski, B.S.Pharm., M.S.
Kristi N.Hofer, Pharm.D.
Manal Abouelkheir, Pharm.D., BCPS, BCPPS
Dennis Baglien, BCPS, BCPPS
Monica Bogenschutz, Pharm.D., BCPS, BCPPS
Karen Brodbeck, RPh, BCPPS
Jesse Cramer, Pharm.D., BCPPS
Tasnim Dawoud, Pharm.D, BCPS, BCPPS
Charisa Flaherty, Pharm.D., BCPPS
Karen Gradischer, Pharm.D., BCPPS
Sarah Hale, Pharm.D., BCPPS
Aaron Harthan, Pharm.D., BCPPS
Sarrah Hein, Pharm.D., BCCPS
Margaret Oates Poisson, Pharm.D., BCPPS
Denise Pinal, Pharm.D., BCPPS
Isabel Porto, Pharm.D., BCPPS
Jena Quinn, Pharm.D.
Emily Rowe, Pharm.D., MS-PREP, BCPPS, BCPS
Ryan Seagren, Pharm.D., BCPPS
Bethany Sharpless, Pharm.D., BCPPS
Marroyln Simmons, Pharm.D., MS, BCPS, BCPPS
Shannon Song, Pharm.D., BCPPS
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.
All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.
- All faculty and planners report no financial relationships relevant to this activity.
Methods and CE Requirements
Activity consists of audio/ video/PDF files, an attestation statement, assessment, and activity evaluation. In order to receive continuing pharmacy education credit, learners must:
- Complete the attestation statement
- Review all content
- Complete and pass the assessment
- Complete the evaluation
- Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Note: Learner must complete and pass the assessment in order to claim continuing pharmacy education credit.
System Technical Requirements
Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.
View the minimum technical and system requirements for learning activities.
These activities were developed by ASHP.